Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...

When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back some of those gains, but still finished the year, as mentioned above, with ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at ...